AI Infrastructure for Life Sciences and Healthcare Founders: Where to Build, Where to Wait

01AI Infrastructure for Life Sciences and Healthcare Founders: Where to Build, Where to Wait

Most founders building AI-enabled companies in life sciences and digital health are making the same infrastructure mistake: they're treating the AI layer as a differentiation problem when it's actually a procurement problem. The companies winning right now aren't the ones who built the most sophisticated inference stack — they're the ones who correctly identified which infrastructure layer they needed to own versus rent, and then moved capital accordingly.

02The Layer Confusion Problem Is Costing You Runway

Here's the pattern I see repeatedly in diligence: a clinical-stage digital health company has allocated 40% of its engineering headcount to maintaining a custom retrieval-augmented architecture sitting on top of a commodity foundation-model tier. The actual differentiation — the clinical ontology, the labeled dataset, the workflow integration with the EHR — is sitting underdeveloped because the team is babysitting infrastructure that a managed service could handle for $8,000 a month.

This isn't a knock on technical ambition. It's a capital-allocation problem. The foundation-model layer has commoditized faster than most founders anticipated. The marginal cost of inference has dropped more than 90% in eighteen months across the major managed-inference providers. That cost curve is not reversing. What's not commoditizing is the proprietary data, the validated clinical workflow, and the regulatory package. Those are the moats.

When the FDA's Digital Health Center of Excellence published its AI/ML action plan update, the through-line was clear: the regulatory scrutiny falls on the clinical decision support function and the change-control process — not the inference architecture underneath it. If your Software as a Medical Device (SaMD) submission is grounded in how your model behaves on your labeled dataset under your intended use, the underlying compute layer is largely invisible to the reviewer. Build where the reviewer looks.

03What the Drug-Discovery Infrastructure Moment Actually Looks Like

In small-molecule and biologics discovery, the infrastructure conversation is different and more consequential. Here, the data-generation layer — assays, proteomics pipelines, cryo-EM throughput — is the infrastructure that determines AI model quality downstream. I've seen Series A companies invest heavily in the AI training stack while running underpowered wet-lab operations that produce noisy training data. The model is only as good as the experimental loop feeding it.

Recursion Pharmaceuticals has been transparent in SEC filings about the economics of its integrated data-generation and AI stack — and the lesson isn't that you need to replicate their capital intensity. The lesson is that the constraint in AI-driven drug discovery is almost never the model architecture. It's the labeled biological data. Recursion's 2023 annual report shows over six petabytes of proprietary cellular imaging data as a core asset. That's the infrastructure worth building.

For founders who can't generate data at that scale, the better path is to identify a narrow biological domain where you can generate high-quality labeled data faster than anyone else — and then build the AI stack on top of that narrow advantage. Broad biological coverage with thin data is a losing infrastructure bet against well-capitalized incumbents.

04The EHR Integration Layer Is Still Broken — and That's Your Opportunity

In clinical AI deployment, the infrastructure bottleneck that's genuinely underappreciated is the EHR integration layer. Founders tend to underestimate how much engineering time gets consumed by HL7 FHIR implementation variance across health system deployments. In practice, a FHIR R4 endpoint at one academic medical center behaves differently enough from another that every new deployment requires meaningful custom work.

ONC's HTI-1 final rule, finalized in late 2023, tightened certified EHR technology requirements around FHIR API performance and information blocking. That's a tailwind — but it's a slow-moving one. Health systems have multi-year upgrade cycles. The companies doing well in clinical AI deployment right now have built a reusable FHIR normalization layer internally and treat it as a competitive asset, not a cost center.

If your go-to-market involves deploying across more than three health systems in the next 18 months, budget for this explicitly. A conservative rule from what I see in deployment-stage companies: expect one senior integration engineer per major EHR platform variant in your target customer base, for the first twelve months of commercial scale. That's not glamorous infrastructure, but it's the actual rate-limiter on revenue.

05Clean Energy and Deep Tech: AI Infrastructure Has a Power Problem

For founders in clean tech and deep tech — particularly those running computationally intensive simulation, materials discovery, or climate-modeling workloads — the AI infrastructure conversation has a physical dimension that software-native founders miss. Training and inference at scale requires power capacity that most commercial data centers are now struggling to provision on reasonable timelines.

The DOE's loan programs office has been explicit that data-center energy demand is a material factor in grid planning through 2030. If your technical roadmap assumes access to large-scale GPU compute 18 months from now at current prices and availability, pressure-test that assumption. Several deep-tech founders I work with have restructured their training pipelines to be more compute-efficient not because of cost, but because reservation queues for large-instance clusters are extending beyond their experimental timelines.

The architectural response worth considering: design your AI training pipeline to be checkpoint-resumable and distribution-agnostic from day one. Teams that locked into single-provider compute dependencies in 2022 spent significant engineering time in 2024 migrating. The flexibility cost is modest; the migration cost is not.

06Regulatory Infrastructure Is AI Infrastructure

This is the point most technical founders deprioritize until it's expensive to fix. If you're building an AI-enabled product that will touch a reimbursable clinical pathway, the regulatory and evidence-generation infrastructure is load-bearing. A 510(k) or De Novo pathway for a SaMD product now routinely requires a predetermined change control plan (PCCP) — the FDA formalized PCCP guidance in 2023 — and building a model update workflow that satisfies a PCCP without triggering a new submission is a non-trivial engineering and regulatory architecture problem.

Clinical-evidence infrastructure — IRB-approved registry studies, real-world evidence collection built into your product from the start, outcome tagging in your data pipeline — is not something you can bolt on at Series B when a payer asks for it. It has to be designed into the product architecture at the point of initial build. The founders who treat regulatory infrastructure as downstream of product infrastructure consistently pay a multiple of the upfront cost to retrofit it later.

The founders building durable companies in our categories right now share one infrastructure instinct: they're ruthlessly clear about what their proprietary asset actually is, and they concentrate engineering capital there. The AI compute layer is a utility. The clinical ontology, the biological dataset, the validated workflow, the regulatory package — those are the infrastructure worth owning. If your current sprint allocation doesn't reflect that priority order, that's the adjustment worth making this quarter.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.